English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Myocardial infarction (MI) continues to represent a major health problem. Improved healing and/or regeneration of infarcted myocardium by injection of progenitor cells has been proposed as a promising approach to prevent cardiac remodelling or even restore myocardial tissue. Several adult stem cell types have shown efficacy in the preclinical setting, including skeletal myoblasts, umbilical cord cells, bone marrow-derived mononuclear cells, and, more recently, adipose tissue-derived stem cells.1,2 Although the debate as to which cell type (or combinations thereof) is best suited for the treatment of acute MI continues, the mesenchymal stem cell (MSC)3 is particularly interesting. Thus, MSCs have been shown to be multipotent, to be capable of homing to infarcted myocardium, inducing angiogenesis and differentiating into myogenic cells, can be easily expanded ex vivo , and are possibly immune privileged.1–4 MSCs can be isolated from several organs, including bone marrow, umbilical cord blood, and adipose tissue, of which subcutaneous fat appears most easily and repeatedly accessible for high yield MSC isolation.2,5Bone marrow-derived MSCs have already shown significant benefit in animal models of MI-induced left ventricular dysfunction.1 For example, in swine with MI produced by a 30 min coronary artery occlusion, allogenic bone marrow-derived MSCs injected into the coronary artery 3 days after reperfusion resulted in a reduction in infarct size and improvement of left ventricular function at 4 weeks follow-up.6 More recently, adipose tissue-derived MSCs have also shown potential in rodent studies. Thus, in models of permanent coronary artery ligation,7–9 MSC application (either as a grafted monolayer7 or via intramyocardial injection8,9), administered either immediately8 or 3–4 weeks after induction of MI,7,9 resulted in improved left ventricular geometry and function another 4–8 weeks later. Although these … *Corresponding author. Tel: +31-10-4638066; fax: +31-10-4089494. E-mail address : d.duncker{at}erasmusmc.nl

Fat is not all bad: how to make good use of adipose tissue